Release date: 24 September 2008
Promoter – Financial Intermediary
Guerbet S.A.
Location
Description
The project focuses on the development of new or improved contrast agents for medical imaging. If successful, they will improve the anatomic visualisation of human organs, the detection of pathologies as well as the functional evaluation of certain organs.
Objectives
The project helps to strengthen the knowledge base and, by default, the market position of a European specialist pharmaceutical company that operates in the segmented global market for medical imaging. Furthermore, the project is expected to increase the small number of contrast agents that are currently on the market.
Sector(s)
Proposed EIB finance (Approximate amount)
Up to EUR 40 million.
Total cost (Approximate amount)
Estimated at around EUR 90 million.
Environmental aspects
The R&D activities encompassed within this project will not materially change current R&D practices and will be carried out within existing facilities, making use of existing laboratories, pilot plants, clinical centres etc. An EIA required by EU Directive 97/11 as amended by Directive 2003/35 is therefore not required. Compliance of R&D activities with relevant EU environmental legislation will be verified during appraisal.
Procurement
The promoter is a private company not operating in the Utilities sector, and is thus not covered by EU directives on procurement.
Status
Signed - 25/03/2009
Disclaimer
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).